W
e read with interest your recent article on the impact of combined oral contraceptives on ocular tissues [1] .
We report a case of a branch retinal vein occlusion (BRVO) associated with use of an etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), an implantable combined hormonal contraceptive, in a young healthy female with no other identifiable risk factors.
A 34-year-old Hispanic female presented with 2mo of decreased vision and metamorphopsia in the right eye. Two months prior, she had started using an etonogestrel/ethinyl estradiol vaginal ring when she developed visual changes; she self-discontinued the vaginal ring one week later but her visual symptoms did not resolve. She denied a history of diabetes, hypertension, thrombotic disorders, smoking, or any prior oral contraceptive use. There is no known family history of any thrombotic disorders. Since this database relied on voluntary reporting, it is difficult to extrapolate the total number of retinal vascular events associated with etonogestrel/ethinyl estradiol. However, given that it constitutes a small proportion of all adverse events associated with NuvaRing, retinal vascular occlusions associated with using this vaginal ring seem to be quite rare, just as it is rare to find retinal vascular occlusions caused by oral contraceptive use [2] . Retinal vein occlusions are a potential cause of visual loss through subsequent macular edema or ischemia and have been associated with hypercoagulable states [3] , including oral contraceptive use [4] . Oral contraceptives contain as little as 20 μg to as much as 50 μg of estrogen [5] . NuvaRing uses a sustained release mechanism that dispenses 120 μg etonogestrel and 15 μg ethinyl estradiol daily over a 3wk period, with 15 μg of estrogen daily considered a low dose [6] . Nevertheless, a review of the literature found that the risk of thromboembolism with NuvaRing is similar to that of combined oral contraceptives [7] [8] . Specific instances of venous thromboembolic events associated with NuvaRing use include deep venous thrombosis and pulmonary embolism [9] [10] , cerebral venous sinus thrombosis [11] [12] [13] , as well as arterial strokes [11] .
Given the BRVO occurred in this patient after her brief use of this implanted combined hormonal contraceptive without other risk factors in an otherwise healthy woman, the role of estrogen must be considered. To our knowledge, this represents the first published case associating an implanted combined hormonal contraceptive device with retinal vascular complications, though several more have been reported to the FDA. We acknowledge the limitations in drawing conclusions from a single case report of a retinal vascular occlusion occurring in association with NuvaRing use. At the same time, we feel that this case is reportable because it raises an important question of whether a lower dose of estrogen than typical oral contraceptives can still be associated with increased hypercoagulability and adverse sequelae, such as in the eye. The relative paucity of retinal vascular occlusions among the entire database of adverse effects of NuvaRing reported to the FDA over its 15y on the market suggests that the incidence is quite rare, but further studies are needed to verify an association between implantable combined hormonal contraceptives and ocular vascular events. 
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